Proof-of-concept data reported for new multi-antigen engager platform (VY-GAGE) designed to overcome solid tumor defense mechanisms Single-step CD45 allogeneic cell…
Our News
We’re on a mission to start a conversation with your customers in this fast connected world.
Single-Step CD45-Engager Strategy Generates Immune-Privileged Cells with Abrogation of Host Cellular Immune Responses Being Developed to Eliminate the Need for…
Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that members of its executive leadership team are scheduled to present and moderate panel sessions at the following upcoming life science conferences this week.
TAMPA, FLORIDA & DUBLIN, IRELAND – March 25, 2020 – Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products.